Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher...

Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA
Researcher to Develop Gestational Diabetes Screening Test

New Screening Test Will Focus on 4.3 Million Annual U.S. Birth Market

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc.
(OTC Bulletin Board: BMSN) and Entest BioMedical Inc., BMSN's wholly-owned
subsidiary, today announced that a contract has been signed with Dr. Brian
Koos, a professor of Obstetrics and Gynecology at the David Geffen School of
Medicine at UCLA for the development, refinement, and validation of a
screening test for gestational diabetes, a glucose intolerance in pregnant
women. Dr. Koos is the developer of a screening test for gestational diabetes
licensed to Entest BioMedical by UCLA. The screening test mitigates the
lengthy process of diagnosing gestational diabetes and would allow for faster
treatment of the disease. Entest is the exclusive licensee for Dr. Koos'
gestational diabetes screening test. Both companies stated that their goal is
to develop a large scale sampling for validation of the screening test with
Food and Drug Administration. The gestational diabetes screening test would
be marketed to hospitals and medical clinics. The U.S. Dept. of Health and
Human Services recently reported that there are approximately 4.3 million live
births in the U.S.

According to Dr. Koos, "There is a very large potential market for our
screening test. Gestational diabetes is diabetes that is found for the first
time when a woman is pregnant. Out of every 100 pregnant women in the U.S.,
three to eight get gestational diabetes. Diabetes means your blood glucose
(or blood sugar) is too high. The body uses glucose for energy, but too much
glucose in the blood can be harmful. An additional concern is that untreated
or uncontrolled gestational diabetes can result in serious problems for your
baby, such as being born very large and with extra fat. Such large infants are
predisposed to birth injury and to obesity later in life. This non-invasive
screening test for gestational diabetes, which is very reliable, is highly
accurate in identifying women with gestational diabetes."

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California
based biotechnology research and development company with a 15,000 square foot
facility that houses two secure cryogenic stem cell banks, three research
laboratories, aseptic cellular/tissue class 10,000/100 processing lab,
hematology, microbiology and flow cytometry laboratories.

About Entest BioMedical Inc.:

Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific
Group Inc. The Company is involved with the development of testing procedures
for diabetes, stem cell research applications for diabetes and other
illnesses. The Company also is involved with medical device development
(including stem cell extraction instrumentation).

Disclaimer:

This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or underlying the
forward-looking statements. The risks and uncertainties to which
forward-looking statements are subject include, but are not limited to, the
effect of government regulation, competition and other material risks.

SOURCE Bio-Matrix Scientific Group, Inc.

Dr. David R. Koos, Chairman and CEO of Bio-Matrix Scientific Group Inc.,
+1-619-702-1404, fax, +1-619-330-2328, info@BMSN.us